Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Xenobiotica ; 48(10): 1028-1036, 2018 Oct.
Article in English | MEDLINE | ID: mdl-28990837

ABSTRACT

1. Quercetin is a dietary flavonoid has extremely low water solubility and found to possess CYP3A inhibitory activity. The purpose of the present study was to evaluate the effect of quercetin and quercetin nanoparticles (NQC) on the pharmacokinetics of bromocriptine (BRO) in rats. 2. NQC prepared by antisolvent precipitation method and characterized by SEM and dissolution test. The following methods were used in this study i.e. in vitro liver and intestinal CYP3A microsomal activity and in vitro non-everted sac method. To confirm these findings, an in vivo pharmacokinetic study was also performed. 3. The results indicate that quercetin significantly (p < 0.05) inhibited the CYP3A activity in liver and intestinal microsomes. In non-everted sac study, the intestinal transport and Papp of BRO were significantly increased in NQC and quercetin groups. Furthermore, in vivo study revealed that the increased levels of Cmax and AUC were comparatively high in NQC pretreated group than quercetin group. In addition, pretreatment with quercetin and NQC significantly (p < 0.05) decreased the mean CL/F and Vd/F of BRO. 4. NQC pretreatment might be result in higher plasma levels of quercetin that could inhibit the CYP3A enzyme and enhanced the bioavailability of BRO.


Subject(s)
Bromocriptine/pharmacokinetics , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics , Cytochrome P-450 CYP3A/metabolism , Intestines/enzymology , Liver/enzymology , Nanoparticles/chemistry , Quercetin/pharmacology , Administration, Oral , Animals , Biological Transport/drug effects , Bromocriptine/administration & dosage , Bromocriptine/blood , Bromocriptine/pharmacology , Calibration , Cytochrome P-450 CYP3A Inhibitors/administration & dosage , Cytochrome P-450 CYP3A Inhibitors/blood , Male , Microsomes/drug effects , Microsomes/enzymology , Nanoparticles/ultrastructure , Permeability , Rats, Wistar
2.
Biomed Chromatogr ; 24(7): 699-705, 2010 Jul.
Article in English | MEDLINE | ID: mdl-19908205

ABSTRACT

A simple and rapid RP-HPLC-DAD method was developed and validated for simultaneous determination of the dopamine antagonists haloperidol, its diazepane analog, and the dopamine agonist bromocriptine in rat plasma, to perform pharmacokinetic drug-interaction studies. Samples were prepared for analysis by acetonitrile (22.0 microg/mL) plasma protein precipitation with droperidol as an internal standard, followed by a double-step liquid-liquid extraction with hexane : chloroform (70:30) prior to C-18 separation. Isocratic elution was achieved using a 0.1% (v/v) trifluoroacetic acid in deionized water, methanol and acetonitrile (45/27.5/27.5, v/v/v). Triple-wavelength diode-array detection at the lambda(max) of 245 nm for haloperidol, 254 nm for the diazepane analog and droperidol, and 240 nm for bromocriptine was carried out. The LLOQ of DAL, HAL, and BCT were 45.0, 56.1, and 150 ng/mL, respectively. In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT. The PK parameters for HAL differed significantly from those previously reported, which may be an indication of a drug-drug interaction.


Subject(s)
Bromocriptine/blood , Chromatography, High Pressure Liquid/methods , Droperidol/analysis , Haloperidol/blood , Animals , Bromocriptine/chemistry , Bromocriptine/pharmacokinetics , Chromatography, High Pressure Liquid/instrumentation , Chromatography, High Pressure Liquid/standards , Drug Interactions , Drug Stability , Haloperidol/chemistry , Haloperidol/pharmacokinetics , Molecular Structure , Rats , Rats, Sprague-Dawley , Reference Standards
3.
Article in English | MEDLINE | ID: mdl-15886074

ABSTRACT

A sensitive LC-MS-MS assay for the quantitative determination of bromocriptine has been developed and validated and is described in this work. The assay involved the extraction of the analyte from 1 ml of human plasma using a solid phase extraction on Oasis MCX cartridges. Chromatography was performed on a Symmetry C18 (2.1 mm x 100 mm, 3.5 microm) column using a mobile phase consisting of 25:75:01 acetonitrile-water-formic acid with a flow rate of 250 microl/min. The linearity was within the concentration range of 2-500 pg/ml. The lower limit of quantification was 2 pg/ml. This method has been demonstrated to be an improvement over existing methods due to its greater sensitivity and specificity.


Subject(s)
Bromocriptine/blood , Chromatography, High Pressure Liquid/methods , Mass Spectrometry/methods , Humans , Quality Control , Reproducibility of Results , Sensitivity and Specificity
4.
Synapse ; 50(2): 110-6, 2003 Nov.
Article in English | MEDLINE | ID: mdl-12923813

ABSTRACT

Bromocriptine is a selective agonist for dopamine D2-receptors and is used in the treatment of Parkinson's disease. In this study, we performed pharmacokinetic and pharmacodynamic (PK/PD) analyses of the antiparkinsonian effect of bromocriptine and evaluated drug-induced contralateral rotations in rats in which unilateral striatal lesions had been generated by microinjection of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle. The plasma concentration (Cp) and D2 receptor occupancy (Phi(D2)) were quantitated by HPLC and with an in vivo back-titration method using [(3)H]-raclopride, respectively. Bromocriptine induced contralateral rotations (E(rot)) in a dose-dependent manner following intraperitoneal administration in an animal model of Parkinson's disease. The Cp of bromocriptine peaked at 15-30 min after the administration and decreased time-dependently, whereas the Phi(D2) of bromocriptine increased gradually for 180 min after administration. The relationship between Cp and E(rot) exhibited an anticlockwise hysteresis, whereas the relationship between Phi(D2) and E(rot) showed a linear correlation. These results suggest that in vivo Phi(D2) is a good pharmacological indicator of the effect of a D2 agonist.


Subject(s)
Bromocriptine/pharmacokinetics , Neostriatum/drug effects , Neural Pathways/drug effects , Neurons/drug effects , Parkinson Disease/drug therapy , Receptors, Dopamine D2/agonists , Substantia Nigra/drug effects , Animals , Bromocriptine/blood , Denervation , Disease Models, Animal , Dopamine Agonists/blood , Dopamine Agonists/pharmacokinetics , Dose-Response Relationship, Drug , Male , Neostriatum/metabolism , Neostriatum/physiopathology , Neural Pathways/metabolism , Neural Pathways/physiopathology , Neurons/metabolism , Oxidopamine , Parkinson Disease/blood , Parkinson Disease/physiopathology , Rats , Rats, Sprague-Dawley , Reaction Time/drug effects , Reaction Time/physiology , Receptors, Dopamine D2/metabolism , Rotation , Substantia Nigra/metabolism , Substantia Nigra/physiopathology
5.
Biol Pharm Bull ; 26(4): 501-5, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12673032

ABSTRACT

Bromocriptine (BRC) has been mainly used for the inhibition of lactation, treatment of menstrual disorders, Parkinson disease, breast tumours, infertility and brain tumours as a dopamine agonist in clinics. But current BRC formulations have some side effects and bioavailability problems because of hepatic first pass effect. Transdermal application could be an alternative route to overcome all these problem and penetration properties of BRC has not been studied yet. Therefore, it was aimed to investigate the effectiveness of transdermal formulation of BRC which is applicable to the skin. For this purpose, a number of BRC gel formulations (Carbopol-934 (C-934), chitosan (CH) and Gantrez-SP215 (G-SP215) were developed and the effectiveness and bioavailability of the formulations were compared in rabbits. Commercial BRC tablets (Parlodel) were also given to rabbits orally and plasma levels were compared. The effects of two different penetration enhancers, sodium taurocholate (ST) and ethoxydiglycol-Transcutol) (TR) on the BRC penetration were also investigated. The skin samples from the dorsal part of the rabbit were removed after CH gel application and investigated under electron microscope to understand the effects of the gel on the penetration and the possible penetration mechanisms through skin were also discussed. In conclusion, CH gel formulation was found to be the best formulation and comparable blood BRC concentrations were obtained when applied to the rabbit skin. Higher blood levels were obtained with the use of CH. The main penetration process was found to be through transcellular route but some other mechanisms were also found to be incorporated, after microscopic investigation. CH gel was found to be a useful carrier for BRC administration through dermal route and the penetration enhancing effect and the mechanism of CH gel were first established in this study. It was concluded that transdermal delivery of BRC may be a very promising alternative route to the oral route for the treatment.


Subject(s)
Bromocriptine/administration & dosage , Bromocriptine/blood , Skin/drug effects , Administration, Cutaneous , Animals , Chemistry, Pharmaceutical , Drug Synergism , Gels , Rabbits , Skin/metabolism
6.
J Chromatogr B Biomed Sci Appl ; 694(2): 415-20, 1997 Jul 04.
Article in English | MEDLINE | ID: mdl-9252057

ABSTRACT

A reliable reversed-phase high-performance liquid chromatographic method has been developed for the determination of bromocriptine (BCT) in plasma and eye tissues. The BCT and propranolol, added as an internal standard (I.S.), were extracted by a liquid-liquid technique followed by an aqueous back-extraction, allowing injection of an aqueous solvent into a 4-microm Nova-Pak C18 column (150x3.9 mm I.D.). The mobile phase was a mixture of 30 parts of acetonitrile and 70 parts of 0.2% triethylamine (pH 3) at a flow-rate of 1 ml/min. Fluorescence detection was at an excitation wavelength of 330 nm and an emission wavelength of 405 nm. The retention times of I.S. and BCT were 4.1 and 11.6 min, respectively. The calibration curve was linear over the concentration range 0.2-10 microg/l for plasma (r>0.999) and vitreous humour (r>0.997) and 1-50 microg/l for aqueous humour (r>0.985). The limit of quantification was 0.2 microg/l for plasma and vitreous humour using a 1-ml sample and was 1 microg/l for aqueous humour using a 0.2-ml sample. The quality control samples were reproducible with acceptable accuracy and precision. The within-day recovery (n=3) was 100-102% for plasma, 91-106% for aqueous humour and 96-111% for vitreous humour. The between-day recovery (n=9) was 90-114% for plasma, 83-115% for aqueous humour and 90-105% for vitreous humour. The within-day precision (n=3) and the between-day precision (n=9) were 1.7-7.0% and 8.1-13.6%, respectively. No interferences from endogenous substances were observed. Taken together, the above simple, sensitive and reproducible high-performance liquid chromatography assay method was suitable for the determination of BCT in plasma and eye tissues following ocular application of BCT for the therapy of myopia.


Subject(s)
Aqueous Humor/chemistry , Bromocriptine/blood , Vitreous Body/chemistry , Animals , Bromocriptine/administration & dosage , Bromocriptine/analysis , Chromatography, High Pressure Liquid , Instillation, Drug , Rabbits , Reproducibility of Results , Sensitivity and Specificity , Spectrometry, Fluorescence
7.
J Endocrinol Invest ; 19(7): 427-32, 1996.
Article in English | MEDLINE | ID: mdl-8884536

ABSTRACT

The oral administration of bromocriptine induces a variety of side-effects in about 50-70% of patients, the most common being nausea and vomiting, probably related to the local gastrointestinal effect of the drug. Nasal administration makes it possible to avoid intestinal and liver metabolism. This study compared the serum concentrations of bromocriptine and prolactin (PRL) in twenty puerperal women who had asked to discontinue breast feeding and were randomized to receive a single oral (2.5 mg) or nasal spray dose (0.8 mg) of bromocriptine. Serum bromocriptine and PRL concentrations were measured at various times before and after drug administration. At 15 min, the circulating concentrations of bromocriptine were about eight times higher after nasal than after oral administration; peak serum concentration (CMax) was reached respectively 45 min and 60 min after administration, and was about three times higher after nasal administration (314 +/- 102 pg/ml vs 112.30 +/- 34.47 pg/ml). The reduction in serum PRL concentrations was also more rapid in the nasally-treated group reaching the normal assay range of < 20 micrograms/l within two as against five hours post-administration. Four orally-treated patients complained of nausea; in the nasally-treated group, six patients reported only a mild endonasal burning that disappeared within a few minutes of administration. Our results suggest that the nasal administration of bromocriptine may lead to a reduction in the required overall dose and fewer gastrointestinal side-effects, and may therefore improve therapy compliance.


Subject(s)
Bromocriptine/pharmacology , Dopamine Agonists/pharmacology , Postpartum Period/blood , Prolactin/blood , Administration, Intranasal , Administration, Oral , Adult , Bromocriptine/administration & dosage , Bromocriptine/blood , Bromocriptine/pharmacokinetics , Cohort Studies , Dopamine Agonists/administration & dosage , Dopamine Agonists/blood , Dopamine Agonists/pharmacokinetics , Female , Humans , Nebulizers and Vaporizers , Postpartum Period/drug effects , Postpartum Period/metabolism , Prolactin/drug effects , Time Factors
8.
Clin Endocrinol (Oxf) ; 36(4): 369-74, 1992 Apr.
Article in English | MEDLINE | ID: mdl-1424170

ABSTRACT

OBJECTIVE: The objective of this study was to assess the relationship of different doses of a long-acting bromocriptine preparation (Parlodel LAR) to the degree and duration of PRL suppression. We also measured circulating bromocriptine levels and altered tolerability of the drug. DESIGN: A double-blind randomized study of three different doses 25, 50 and 100 mg of Parlodel LAR. PATIENTS: Twenty-one female patients (seven patients/dose) with both tumoral and non-tumoral hyperprolactinaemia. MEASUREMENTS: After a single injection of Parlodel LAR 25, 50 or 100 mg, serum PRL and plasma bromocriptine levels were assessed during a follow-up of 60 days together with changes in clinical symptoms and signs of hyperprolactinaemia. RESULTS: Serum PRL levels normalized in 19 of 21 patients. The suppression of PRL secretion lasted 28 days in four of seven patients treated with either 25 or 50 mg Parlodel LAR and in five of seven patients who received Parlodel LAR 100 mg. In five of seven patients treated with the 100 mg dose, serum PRL levels were still within the normal range on day 60. Plasma bromocriptine levels remained therapeutically active for 28 days in all three groups. On day 60 they were within the therapeutic range only in the 100 mg group. Clinical data show a rapid disappearance of symptoms and signs of hyperprolactinaemia. Adverse events were mostly mild and transient. CONCLUSIONS: These data support the excellent efficacy and good tolerability of Parlodel LAR in patients with hyperprolactinaemia.


Subject(s)
Bromocriptine/administration & dosage , Hyperprolactinemia/drug therapy , Adult , Bromocriptine/blood , Delayed-Action Preparations , Double-Blind Method , Drug Administration Schedule , Female , Humans , Hyperprolactinemia/blood
9.
Eur J Drug Metab Pharmacokinet ; 16(3): 177-81, 1991.
Article in English | MEDLINE | ID: mdl-1814735

ABSTRACT

The effect of food and metoclopramide on the pharmacokinetics of bromocriptine was investigated in 7 healthy subjects. Plasma concentrations of bromocriptine were measured by radioimmunoassay after a single oral dose of 7.5 mg bromocriptine. Maximal plasma concentrations of bromocriptine were slightly lower when the drug was given after breakfast. Bioavailability of the drug was not significantly reduced by food nor by metoclopramide pre-treatment. Side effects of bromocriptine were considerably reduced by metoclopramide pre-treatment (0.5 mg/kg); the decrease was about 83% as estimated from Table II.


Subject(s)
Bromocriptine/pharmacokinetics , Food , Metoclopramide/pharmacology , Administration, Oral , Adult , Biological Availability , Bromocriptine/administration & dosage , Bromocriptine/adverse effects , Bromocriptine/blood , Humans , Male , Radioimmunoassay
10.
Fertil Steril ; 55(5): 882-4, 1991 May.
Article in English | MEDLINE | ID: mdl-2022266

ABSTRACT

OBJECTIVE: To compare the circulating levels of bromocriptine after oral and vaginal administration of the drug. DESIGN: Experimental PARTICIPANTS: Seven ovulatory female volunteers and one hyperprolactinemic patient. INTERVENTIONS: Ovulatory volunteers were randomized to receive either oral or vaginal bromocriptine (2.5 mg). In a second session, the subjects were crossed-over to bromocriptine by the alternate route. An additional hyperprolactinemic patient received vaginal bromocriptine only. MAIN OUTCOME MEASURE: Serum bromocriptine and prolactin (PRL) levels were measured hourly for 12 hours in the normal volunteers and for 10 hours in the hyperprolactinemic patient. RESULTS: Circulating bromocriptine levels were significantly higher after vaginal bromocriptine after the 7th hour (P less than 0.05). The reduction in serum PRL was significantly greater after oral administration between 2 and 6 hours. CONCLUSIONS: Vaginally administered bromocriptine may result in a reduction in the overall dose required, thereby improving compliance without compromising therapeutic efficacy.


Subject(s)
Bromocriptine/pharmacokinetics , Vagina , Administration, Oral , Bromocriptine/administration & dosage , Bromocriptine/blood , Female , Humans , Hyperprolactinemia/blood , Kinetics , Prolactin/blood , Vagina/metabolism
12.
Br J Obstet Gynaecol ; 97(6): 527-32, 1990 Jun.
Article in English | MEDLINE | ID: mdl-2378830

ABSTRACT

Recently, long-acting injectable forms of bromocriptine have become available for the prevention of lactation. The first developed depot-form was very effective, but had the disadvantage of a slowly metabolized carrier. we investigated the pharmacokinetics, efficacy, tolerance and safety of 40 and 50 mg of a new rapidly eliminated depot-form in 61 postpartum women. Bromocriptine rapidly increased after injection and prolactin was effectively suppressed during the study-period of 60 days. Overall efficacy was very good or good in 98% and no rebound lactation occurred. Sixteen women experienced side effects. Tolerance at the injection site was good and safety tests did not show abnormalities. There were no differences between the two dosages. We conclude that this new depot-bromocriptine is a safe, well tolerated and effective drug in the suppression of prolactin and the prevention of post-partum lactation.


Subject(s)
Bromocriptine/administration & dosage , Lactation/drug effects , Adult , Bromocriptine/blood , Bromocriptine/pharmacokinetics , Delayed-Action Preparations , Depression, Chemical , Drug Administration Schedule , Drug Tolerance , Female , Humans , Lactation/blood , Postpartum Period/blood , Pregnancy , Prolactin/blood
13.
Clin Neuropharmacol ; 12(5): 440-7, 1989 Oct.
Article in English | MEDLINE | ID: mdl-2611767

ABSTRACT

The administration of bromocriptine in addition to levodopa in Parkinson's disease produces beneficial results. Several hypotheses have explained the advantage of the combined treatment by a pharmacodynamic interaction in the striatum. However, no study has considered the possibility that levodopa modifies the kinetics of bromocriptine. In the present study performed with parkinsonian patients, we measured blood levels of bromocriptine (by radioimmunoassay) at 0, 30, 60, 90, 120, 180, and 240 min after the oral administration of bromocriptine alone and together with 250 mg levodopa plus 25 mg DCI. After loading of bromocriptine alone, we found mean peak levels at 60 min (1.42 ng/ml) and at 90 min (1.82 ng/ml). These values were reduced by levodopa (0.97 ng/ml at 60 min and 0.93 ng/ml at 90 min). Although we did not observe substantial clinical differences among the groups after the drug challenge (Webster scale), this study supports our previous findings and suggests that one of the advantages of a combined treatment may result from a modification of the plasma levels of bromocriptine by levodopa. A "smoothing" of the plasma bromocriptine curve possibly avoids sudden oscillations of the drug and enables a more "stable" penetrability of the medication into the central nervous system. Therefore long-term combined treatment is advised in preference to bromocriptine alone.


Subject(s)
Adjuvants, Pharmaceutic , Bromocriptine/pharmacokinetics , Levodopa/pharmacology , Parkinson Disease/metabolism , Aged , Bromocriptine/blood , Drug Interactions , Female , Humans , Male , Middle Aged
14.
Minerva Ginecol ; 41(3): 157-60, 1989 Mar.
Article in Italian | MEDLINE | ID: mdl-2666885

ABSTRACT

A woman who presented with amenorrhea and galactorrhea with a large prolactinoma (8.5 mm) which regressed on bromocriptine therapy is described. When treatment with bromocriptine was instituted (10 mg/daily) mean serum prolactin concentration fell from 490 ng/ml to 108 ng/ml. Despite a progressive reduction in size up to disappearance of the adenoma after the first 5 years of therapy, prolactin levels remained high. Bromocriptine treatment was stopped after 6 years, when pregnancy was diagnosed. Pregnancy proceeded without complications and lactation was initiated and maintained. After 8 months of breast-feeding, menstrual function resumed spontaneously and bromocriptine therapy was no longer required. Bromocriptine can cause not only a decrease in serum prolactin levels but also a regression in the size of prolactinomas in hyperprolactinemic women. No problems associated with pregnancy and/or breast-feeding were noted in these patients.


Subject(s)
Bromocriptine/therapeutic use , Hyperprolactinemia/drug therapy , Pituitary Neoplasms/drug therapy , Pregnancy Complications/drug therapy , Prolactinoma/drug therapy , Adult , Amenorrhea/etiology , Bromocriptine/blood , Female , Galactorrhea/etiology , Humans , Hyperprolactinemia/blood , Hyperprolactinemia/complications , Pituitary Neoplasms/complications , Pregnancy , Pregnancy Complications/blood , Prolactin/blood , Prolactinoma/blood , Prolactinoma/complications
15.
Arzneimittelforschung ; 38(10): 1529-32, 1988 Oct.
Article in English | MEDLINE | ID: mdl-3196397

ABSTRACT

A new MS/MS assay for the quantitative determination of bromocriptine in body fluids is presented. The selective reagent gas in combination with the registration of selected, characteristic negative ions (SIM) after collision activated decomposition (CAD) in a Triple-Stage-Quaddrupole-mass spectrometer, provides an exceptional selective and sensitive assay in the low pg/ml range. The lower limit of detection was about 1 pg/ml (at optimal measuring conditions) and the calibration curve was linear in the range of 10-200 pg/ml. The coefficient of variation for the imprecision and inaccuracy data was typically below 10%; the recovery from plasma always exceeded 75%. The sample introduction to the mass spectrometer was done by a direct exposure probe (DEP). Thus, the method is well suited for the reliable, rapid processing of large sample numbers generated e.g. from clinical studies evaluating the pharmacokinetics and/or bioavailability/bioequivalence of different formulations or from drug monitoring/clinical response programs. The assay has been successfully approved in several clinical studies evaluating different bromocriptine preparations.


Subject(s)
Bromocriptine/blood , Biological Availability , Bromocriptine/pharmacokinetics , Calibration , Chemical Phenomena , Chemistry , Ergotamine , Humans , Mass Spectrometry/standards , Predictive Value of Tests , Reference Standards
16.
Acta Endocrinol (Copenh) ; 116(2): 275-81, 1987 Oct.
Article in English | MEDLINE | ID: mdl-3661064

ABSTRACT

Some patients with hyperprolactinaemia are unable to tolerate even low doses of oral bromocriptine. In such cases, it is difficult to predict whether serum prolactin might be normalized if higher doses could be tolerated, or whether true resistance to bromocriptine is present. We have investigated 8 such patients who were subjected to a dopamine infusion (4 micrograms/kg per min for 4 h), followed by an injection of 50 mg of depot bromocriptine on a separate occasion. Serum prolactin was normalized in 4 patients during dopamine, and in 6 patients 12-48 h following depot bromocriptine. The 2 patients who failed to respond to depot bromocriptine also failed to respond to high oral doses of bromocriptine, while the remaining 6 patients were successfully transferred to oral bromocriptine without adverse reactions after the depot preparation was administered, and with a normalization of serum prolactin. It is concluded that depot bromocriptine may represent a better predictor of true unresponsiveness to dopamine agonist therapy than a dopamine infusion, and may also allow for initiation onto oral therapy of previously intolerant patients.


Subject(s)
Bromocriptine/administration & dosage , Dopamine/administration & dosage , Administration, Oral , Adult , Bromocriptine/adverse effects , Bromocriptine/blood , Delayed-Action Preparations , Drug Tolerance , Female , Humans , Hyperprolactinemia/drug therapy , Infusions, Intravenous , Injections, Intravenous , Male
17.
Ann Clin Biochem ; 23 ( Pt 6): 686-93, 1986 Nov.
Article in English | MEDLINE | ID: mdl-3800295

ABSTRACT

Plasma bromocriptine assays must have high sensitivity because plasma concentrations are low, and high specificity because bromocriptine is extensively metabolised. This paper describes the simple preparation of a radioiodine-labelled derivative of dihydroergocriptine and its use in a radioimmunoassay employing an antiserum directed against the intact bromocriptine molecule. The method could measure plasma bromocriptine at concentrations of 0.05 nmol/L, had between-assay coefficients of variation of less than 10% and was more convenient than previous assays using tritium radiolabels.


Subject(s)
Bromocriptine/blood , Radioimmunoassay/methods , Adenoma/blood , Adenoma/drug therapy , Bromocriptine/therapeutic use , Humans , Iodine Radioisotopes , Pituitary Neoplasms/blood , Pituitary Neoplasms/drug therapy , Prolactin/blood
18.
Obstet Gynecol ; 67(1): 82-5, 1986 Jan.
Article in English | MEDLINE | ID: mdl-3940343

ABSTRACT

A long-acting form of bromocriptine, a prolactin (PRL) secretion inhibitor, was administered to 122 postpartum women in single intramuscular injections of 20 (N = 24), 30 (N = 22), 40 (N = 46), and 50 mg (N = 30). In 91 women the substance was administered immediately after delivery to prevent galactopoiesis and in the remaining 31 women to inhibit established lactation. Effectiveness was estimated by the absence of breast engorgement and of milk secretion. Successful prevention or inhibition of lactation was highest among women receiving 50 mg bromocriptine (97%), and comparison between dosages revealed a close linear dose-response relationship (r = 0.98). Persistent and significant (P less than .001) PRL inhibition could be recorded for up to 22 days in successfully treated puerperas in comparison with 12 normally breast-feeding women who served as control subjects. No significant side effects or local reactions were recorded. Eleven of 46 postpartum women receiving 20 or 30 mg bromocriptine experienced onset of milk secretion or lactation rebound, and responded to oral administration of the drug. The presence of milk was associated with plasma PRL concentrations persistently above 25 ng/mL in all of them, whereas nine women in the same dosage range in whom lactation suppression was effective exhibited values below this limit. Dose-response data allow the establishment of a putative PRL threshold for induction of milk secretion of about 25 ng/mL. Maintenance of plasma PRL values below this limit prevents lactogenesis and inhibits lactopoiesis.


Subject(s)
Bromocriptine/therapeutic use , Lactation/drug effects , Bromocriptine/administration & dosage , Bromocriptine/blood , Drug Administration Schedule , Female , Humans , Injections, Intramuscular , Kinetics , Postpartum Period , Pregnancy , Prolactin/metabolism , Time Factors
19.
Acta Paediatr Scand ; 75(1): 106-10, 1986 Jan.
Article in English | MEDLINE | ID: mdl-3953265

ABSTRACT

Somatomedin and bromocriptine levels were measured before and after 3 months of bromocriptine treatment (5 mg/day) in the sera of 16 tall adolescents with excessive adult height prediction. Somatomedins were measured by RIA for somatomedin C and IgFII and by measuring thymidine incorporation into human lectin-activated lymphocytes. Mean +/- SEM levels of bromocriptine after three months of treatment were 0.61 +/- 0.08 ng/ml. No changes in radioimmunoassayable somatomedin C were observed after bromocriptine intake respectively 1.34 +/- 0.17 U/ml before and 1.4 +/- 0.01 U/ml during treatment. On the opposite a significant decrease of thymidine activity (p less than 0.002) from 1.45 +/- 0.17 U/ml to 1.12 +/- 0.19 U/ml was observed. No changes of IgFII levels were observed in the sera of the 8 patients where they were measured. In order to test a possible direct effect of bromocriptine on peripheral tissues bromocriptine mesylate was added in somatomedin bioassays. Inhibitory effect of bromocriptine in vitro is seen at higher levels (1 microM) compared to the circulating one (1 nM). This study demonstrates that the major effect of bromocriptine which is the acceleration of bone maturation is not related to changes in somatomedin C.


Subject(s)
Body Height/drug effects , Bromocriptine/pharmacology , Somatomedins/blood , Bromocriptine/blood , Female , Humans , Insulin-Like Growth Factor I/blood , Insulin-Like Growth Factor II/blood , Male , Thymidine/blood
20.
Acta Pharmacol Toxicol (Copenh) ; 55(3): 168-73, 1984 Sep.
Article in English | MEDLINE | ID: mdl-6507109

ABSTRACT

Oral amantadine 100 mg and bromocriptine 2.5 + 2.5 mg, alone and in combination with ethanol (1 g/kg), were investigated in two placebo-controlled, double-blind and cross-over trials. In the first trial the psychomotor effects of amantadine and bromocriptine were compared to those of placebo, and in the second trial ethanol was added to the treatment. Bromocriptine lowered serum prolactin levels, thus confirming its absorption. Amantadine and bromocriptine alone had no psychomotor effects but unpleasant sensations, nausea and dizziness were reported after bromocriptine. Ethanol impaired performance in terms of impaired coordinative and reactive skills, lowered tapping speed, prolonged critical flicker interval and reduced gaze nystagmus angle (P less than 0.05 to 0.001; two-way ANOVA). Subjectively, ethanol induced mental slowness, clumsiness and impairment of performance (P less than 0.05 to 0.001). Amantadine and bromocriptine failed to counteract any of these ethanol-induced changes. It is concluded that in man, an acute dopaminergic activation by amantadine or bromocriptine does not significantly modify the psychomotor effects of ethanol.


Subject(s)
Alcoholic Intoxication/drug therapy , Amantadine/therapeutic use , Bromocriptine/therapeutic use , Psychomotor Performance/drug effects , Adult , Amantadine/blood , Bromocriptine/blood , Double-Blind Method , Humans , Kinetics , Male , Prolactin/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...